Abstract: There is provided a compound which can be used for therapy of diseases in which 11?-hydroxysteroid dehydrogenase type 1 (11?-HSD1) participates, in particular diabetes, insulin resistance. It has been found that a triazole derivative wherein the triazole ring is substituted with a trisubstituted methyl group in the 2-position or a pharmaceutically acceptable salt thereof has a strong 11?-HSD1 inhibitory activity. Moreover, the triazole derivative of the invention exhibits an excellent blood-glucose level-lowering action and hence can be used for therapy of diabetes, insulin resistance.

Abstract: In a nonaqueous electrolyte secondary battery having a positive electrode containing a positive electrode active material, a negative electrode containing a negative electrode active material, and a nonaqueous electrolyte, as the positive electrode active material or as the negative electrode active material, a mixture containing molybdenum dioxide and lithium titanate in a weight ratio (molybdenum dioxide:lithium titanate) of 90:10 to 50:50 is used.

Abstract: A non-aqueous electrolyte secondary battery includes a positive electrode (1) containing lithium cobalt oxide as a positive electrode active material, a negative electrode (2) containing molybdenum dioxide as a negative electrode active material, and a non-aqueous electrolyte. The mass ratio of the negative electrode active material to the positive electrode active material is within the range of from 0.725 to 0.480. The conductive agent of the negative electrode consists of a carbon material having a lattice constant C0 along a stacking direction of from 6.7 ? to 6.8 ?, as determined by X-ray diffraction, or the negative electrode contains no conductive agent made of carbon material.

Abstract: In a nonaqueous electrolyte secondary battery having a positive electrode containing a positive electrode active material, a negative electrode containing a negative electrode active material, and a nonaqueous electrolyte, as the positive electrode active material or as the negative electrode active material, a mixture containing molybdenum dioxide and lithium titanate in a weight ratio (molybdenum dioxide:lithium titanate) of 90:10 to 50:50 is used.

Abstract: A diagnostic device for a fuel vapor treatment system having: a canister that captures fuel vapor generated in a fuel tank; a purge passage for purging fuel vapor from the canister to an intake passage of an internal combustion engine; a purge valve provided in the purge passage to adjust a flow rate of fuel vapor; a processing device that depressurize an fuel vapor path extending from the fuel tank to the purge valve via the canister by a pump and performs a diagnostic processing for diagnosing a leak of fuel vapor from the fuel vapor path based on a change in pressure in the fuel vapor path during depressurization; and an angle detection device that detects an angle of inclination of the vehicle. The processing device determines, based on an inclination angle of the vehicle detected by the angle detection device, whether the diagnostic processing can be performed.

Abstract: A polymer for bonding the positive electrode and negative electrode of a lithium secondary battery, which includes a positive electrode, a negative electrode and an electrolyte solution, with a separator arranged between the positive electrode and the negative electrode. The polymer contains a cationically polymerizable monomer unit (A), a monomer unit (B) providing affinity to the electrolyte solution, a monomer unit (C) providing poor solubility to the electrolyte solution, and a monomer unit (D) containing an anionic or nonionic hydrophilic group. This polymer can be obtained through radical polymerization such as emulsion polymerization or suspension polymerization, and is characterized by having a dissolution rate into a mixed solvent of ethylene carbonate (EC) and diethyl carbonate (DEC)[EC:DEC=5:5 (weight ratio)] of not more than 10% by weight.

Abstract: The present invention relates to a new cyclic peptide compound or a salt thereof, which has anti-hepatitis C virus activities based on inhibitory activity against the RNA replication of hepatitis C virus replicon, to a process for preparation thereof comprising a rearrangement reaction under a mild acidic condition and the following amino acid changing reactions etc., to a pharmaceutical composition comprising the same, and to a method for prophylactic and/or therapeutic treatment of hepatitis C in a human being or an animal.

Abstract: A lithium secondary battery including a positive electrode, a negative electrode, a separator, and a nonaqueous electrolyte including a solute and a solvent, wherein the separator is made of glass fibers and the negative electrode includes a lithium-aluminum-manganese alloy as an active material.

Abstract: [Problem] To provide a compound which may be used in treating diseases in which 11?-hydroxysteroid dehydrogenase type 1 (11?-HSD1) is concerned, especially diabetes and insulin resistance. [Means for Solution] It was found that a triazole derivative or a pharmaceutically acceptable salt thereof, in which the 3-position of triazole ring is substituted with a trisubstituted methyl group and the 5-position is substituted with a lower alkyl, cycloalkyl or the like, has a strong 11?-HSD1-inhibitory activity. In addition, since the triazole derivative of the present invention shows excellent blood glucose-lowering action, it may be used in the treatment of diabetes and insulin resistance.

Abstract: An infusion vessel has a vessel body having an internal cavity to serve as an infusion medium space, a cylindrical discharge mouth continuing from a lower portion of the vessel body, a medicine chamber disposed in the discharge mouth and kept airtight against ambient air, and a separator intervening between the infusion medium space and the medicine chamber so as to keep the space in a liquid-tight state against the holder. The separator is subject to displacement, rotation or deformation such as to bring the infusion medium space into communication with the medicine chamber, so that the infusion vessel can be made ready for use by conducting a simple operation to mix the medicine with the infusion medium that have been separated from each other within the vessel during its normal state before use.

Abstract: The invention provides a non-aqueous electrolyte battery characterized in that: an active material of the positive electrode includes lithium manganese oxide; the shut-down temperature of the separator is 162° C. or lower; and the area contraction ratio of the separator at 120° C. is 15% or less.

Abstract: A nonaqueous electrolyte secondary battery including a positive electrode containing a positive active material, a negative electrode containing a negative active material and a nonaqueous electrolyte. The secondary battery contains, as the negative active material, a lithium-containing molybdenum oxide represented by a chemical formula LixMoO2 (0.05?x?0.25) when in a fully discharged state. The lithium-containing molybdenum oxide can be obtained by allowing lithium to react to molybdenum dioxide (MoO2) electrochemically, for example.

Abstract: It is intended to provide a protein participating in the regulation of sugar production, a polynucleotide encoding the same, a method of screening a compound participating in the regulation of sugar production and a drug for treating or preventing diabetes which contains the compound participating in the regulation of sugar production. A polynucleotide encoding a protein specifically binding to a substance WF00144 is found out from rat liver cells and thus a protein participating in the regulation of sugar production and a polynucleotide encoding the same are provided. Moreover, a method and a substance relating to a method of treating and preventing diabetes are found out and thus a method of treating diabetes relating to the regulation of sugar production relating to the method of treating and preventing diabetes is provided.

Abstract: A container cap capable of securely locking a plug member to a mouth by a locking member when the cap is installed and capable of being easily and rapidly removed from the mouth together with the plug member merely by pulling out a holder member upward in unplugging, comprising the locking member 13 covered on the container mouth 2 so as to hold the rubber plug 3 and the holder member 14 fitted to the outer peripheral sides of the plurality of locking pieces 12 of the locking member 13. In each locking piece 12, an upper side part 12U is connected to a lower side part 12D through a thin-walled bending part 12a at the vertical intermediate part of the locking piece 12, the upper side part 12U is locked to the rubber plug 3 from the lower side with the holder member 14 fitted to the outer peripheral side thereof, and the lower side part 12D is locked to the container mouth 2 from the lower side with the holder member 14 fitted to the outer peripheral side thereof.

Abstract: [Problem] There is provided a compound which can be used for therapy of diseases in which 11?-hydroxysteroid dehydrogenase type 1 (11?-HSD1) participates, in particular diabetes, insulin resistance. [Means for Solution] It has been found that a triazole derivative wherein the triazole ring is substituted with a trisubstituted methyl group in the 2-position or a pharmaceutically acceptable salt thereof has a strong 11?-HSD1 inhibitory activity. Moreover, the triazole derivative of the invention exhibits an excellent blood-glucose level-lowering action and hence can be used for therapy of diabetes, insulin resistance.

Abstract: In a nonaqueous electrolyte secondary battery having a positive electrode containing a positive electrode active material, a negative electrode containing a negative electrode active material, and a nonaqueous electrolyte, as the positive electrode active material or as the negative electrode active material, a mixture containing molybdenum dioxide and lithium titanate in a weight ratio (molybdenum dioxide:lithium titanate) of 90:10 to 50:50 is used.

Abstract: This invention provides a container set for mixing at the time of administration allowing a secure mixing operation in administration without dripping chemicals by maintaining the sealed state of the mouth of liquid container particularly until the containers are connected to each other for mixing while storing two contents in the containers, respectively, wherein a tuber plug 5 is detachably fitted to the mouth part 4 of a vial 1 and a cap 30 is fitted to the mouth part 22 of the liquid container 2. The cap 30 has a first structure 31 fitted liquid-tightly to the mouth part 22 and a second structure 32 fitted liquid-tightly to the first structure 31 and having a connection port part 32a connectable liquid-tightly to the mouth part 4.

Abstract: A nonaqueous electrolyte secondary battery including positive and negative electrodes capable of occluding and releasing lithium and a nonaqueous electrolyte and in which the negative electrode includes a foamed metal containing silicon as an active material therein.

Abstract: A lithium primary battery contains a positive electrode and a negative electrode, wherein the positive electrode comprises manganese dioxide containing boron and phosphorus and the negative electrode comprises lithium or lithium alloy.

Abstract: The present invention provides an infusion vessel, which is capable of separately containing a drug and a infusion liquid in a sterile manner and mixing the drug with the infusion liquid in a sterile manner by a simple operation for use, while ensuring the sterility of a connector thereof. The infusion vessel according to the present invention comprises a bag (2) for containing a infusion liquid, a two-mouth vial (3) for containing a drug, and a joint (4) connecting the bag and the vial. A lower mouth portion (33) of the vial (3) is sealed with a rubber plug (7). The joint (4) is air-tightly connected to a liquid outlet port (21) provided in a bottom portion of the bag (2), and extends downward. The joint (4) has an opening (46) for communication between the inside and the outside thereof. An O-ring (6) and an intermediate rubber plug (5) are respectively attached to the joint (4) above and below the opening (46), and fitted in the upper mouth portion (32) of the vial (3) in an axially movable manner.